Treatment of posthepatitic cirrhosis by fuzheng huayu tablet for reinforcing qi and resolving stasis

Chinese Journal of Integrative Medicine

Volumn 19, Issue 4, 2013, Pages 289-296

  Deng, Xin ^a   Liang, Jian ^a   Liu, Zhen Wei ^a   Wu, Fa Sheng ^a   Li, Xuan ^a  

^a RUIKANG HOSPITAL AFFILIATED TO GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Blood activating; Clinical trial; Fuzheng Huayu Tablet; Posthepatitic cirrhosis; Stasis resolving

Indexed keywords

ALBUMIN; BILIRUBIN; CHINESE DRUG; COLLAGEN TYPE 4; FIBRINOGEN; FUZHENG HUAYU TABLET; HYALURONIC ACID; PLACEBO; UNCLASSIFIED DRUG; FUZHENG HUAYU; HERBACEOUS AGENT;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; ASCITES; BLOOD CLOTTING; CHINESE MEDICINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS VARICES; FEMALE; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER CONGESTION; LIVER FIBROSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PORTAL VEIN BLOOD FLOW; POSTHEPATIC LIVER CIRRHOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPLENIC VEIN; SURVIVAL RATE; TABLET FORMULATION; THROMBIN TIME; TREATMENT DURATION; VEIN BLOOD FLOW; YOUNG ADULT; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; LIVER FUNCTION TEST; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; TABLET; TREATMENT OUTCOME;

ADULT; AGED; ASCITES; BLOOD COAGULATION; DRUGS, CHINESE HERBAL; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; QI; QUALITY OF LIFE; SURVIVAL ANALYSIS; TABLETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885587834     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-013-1433-7     Document Type: Article

References (34)

1. Seung H P, Dong J K, Jae Y C, Cho SW, Hwang SG, Lee YJ, et al. Non-invasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Clin Biochem 2010;43:877-881.
2. Sophie L, Boris J, Fatima T-C, Pascale G, Ariane M. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605-628.
3. Li WY, Jiang YF, Jin QL, Zhang H, Feng XW, Niu JQ. Immunologic characterization of posthepatitis cirrhosis caused by HBV and HCV infection. J Biomed Biotechnol doi:10.1155/2010/138237.
4. Anna S, Brian J. Chronic hepatitis B. Hepatology 2007;45:507-538.
5. Ganne-Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-1517.
6. Jordi B, Morris S, Josep M. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430.
7. Lu ZY, Zhong NS, eds. Internal medicine. 7th ed. Beijing: People's Medical Publishing House; 2008:446-454.
8. Yang HZ, Wang FL, Wang YZ, Shen WS, Xu GL, Yang YW, et al. The clinical study on chronic hepatitis B treated by the four-step therapeutics of traditional Chinese medicine. Chin Med Mater (Chin) 2006;29:748-752.
9. Shi WQ, Ru QJ, Cai GY. Effect of umbilical sticking therapy with Qitou Xiaogu plaster in treating liver cirrhosis patients with portal hypertension. Chin J Integr Tradit West Med (Chin) 2008;28:642-645.
10. Deng X, Liang J, Wu FS, Li YB, Tang FY. Effects of traditional Chinese medications on quality of life in patients with liver cirrhosis. Lishizhen Med Mater Med Res (Chin) 2010;21:3314-3316.
11. Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007;27:879-890.
12. Li YM, Yang HZ, Guan WB, Ke QS, Dai M, Xie HP, et al. Therapeutic effect of traditional Chinese medicine on coagulation disorder and accompanying intractable jaundice in hepatitis B virus-related liver cirrhosis patients. World J Gastroenterol 2008;14:6060-6064.
13. Huang J, Huang H, Jiao Y, Ai G, Huang T, Li L, et al. Effect of Anluohuaxian Tablet combined with gamma-IFN on schistosomal liver fibrosis. J Huazhong Univ Sci Technol Med Sci (Chin) 2009;29:53-58.
14. Tong GD, Zhou DQ, He JS, Zhang L, Chen ZF, Xiao CL, et al. Clinical research on navel application of Shehuang Paste combined with Chinese herbal colon dialysis in treatment of refractory cirrhotic ascites complicated with azotemia. World J Gastroenterol 2006;12:7798-7804.
15. Wen J, Shen WL, Yang SH. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis. Hepatobiliary Pancreat Dis Int 2006;5:224-227.
16. Digestive Disease Committee, Chinese Association of Integrative Medicine. Program for diagnosis and treatment of liver cirrhosis with integrative Chinese and Western medicine (draft). Chin J Integr Tradit West Med (Chin) 2004;24:869-871.
17. Society of Infectious and Parasitic diseases and Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of viral hepatitis. Chin J Infect Dis (Chin) 2001;19(1):56-62.
18. WHO. World Health Organisation WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment. Geneva, 1996.
19. Hao YT, Fang JQ. Chinese version of WHOQOL: introduction and administration. Modern Rehabil (Chin) 2000;4:1123-1124.
20. Digestive Disease Committee, Chinese Association of Integrative Medicine. Criteria for clinical diagnosis, syndrome differentiation and response evaluation for liver cirrhosis (trial edition). Chin J Integr Tradit West Med (Chin) 1994;14:237-238.
21. State Administration of Traditional Chinese Medicine of the People's Republic of China. Criteria for diagnosis and treatment of diseases in traditional Chinese medicine. Nanjing: Nanjing University Press; 1994:276.
22. Cai L, Wen LM, Qin G, Chen P, Chen JP. Endoscopic injection of domestically produced tissue adhesives combined with ligation in the treatment of esophagogastric varices. J Milit Surg Southwest China (Chin) 2010;12:866-867.
23. Ren JX. An investigation into incubative pathogen. Chin Med Mod Dist Educ China (Chin) 2003;6(2):8-9.
24. Kuang WH. An introduction to the experience of Professor XU Xin-mei in treating chronic hepatitis B. J New Chin Med (Chin) 2006;38(9):13-14.
25. Gu J, Hong JH, Xu LM, Zhang Q. Effects of "Fuzheng Huayu Capsule" on portal hemodynamics in patients with liver cirrhosis. Shanghai J Tradit Chin Med (Chin) 2005;39(11):31-32.
26. Wang Y. Effects of "Fuzheng Huayu Capsule" on liver fibrosis in 60 patients. Shaanxi J Tradit Chin Med (Chin) 2011;32:1117-1118.
27. Zhu XL. Clinical observation of effects of "Fuzheng Huayu Capsule" on liver fibrosis. China Pract Med (Chin) 2011;6:136-137.
28. Xia XF. Clinical observation of effects of "Fuzheng Huayu Capsule" on portal hypertension in patients with liver cirrhosis. J Emerg Tradit Chin Med (Chin) 2010;19:1119-1120.
29. Moller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 2011;1254-1259.
30. Park S, Kim SH, Ropella GE, Roberts MS, Hunt CA. Trancing multiscale mechanisms of drug disposition in normal and diseased livers. J Pharmacol Exp Ther 2010;334:124-136.
31. Rossle M, Gerbes A. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010;59:988-1000.
32. Kim YK, kim YK, Shim SS. Thoracic complications of liver cirrhosis: radiologic findings. Radio Graph 2009;29:825-837.
33. Li WW, Li Q, Wang JB, Li XY, Zhang LX, An Y, et al. A study of the quality of life in patients with hepatitis B. Chin J Hepatol (Chin) 2007;15:312-313.
34. Liang R, Liu XY, Zhang HQ, Li TH. Quality of life in patients with liver cirrhosis survey. Mod Prevent Med (Chin) 2011;38:1884-1885.